Infectious Diseases
Name | Preis | |||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Human Anti-SARS-CoV-2 Spike-RBD (Clone s309) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone s309) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD (Clone s309) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone s309) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD (Clone AbA128) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone AbA128) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD (Clone AbA128) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone AbA128) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD (Clone AbE450) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone AbE450) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD (Clone AbE450) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD (Clone AbE450) mAb | ||||||||||||||||
|
||||||||||||||||||
Rabbit Anti-SARS-CoV-2 Nucleocapsid pAb | Anmelden | Rabbit Anti-SARS-CoV-2 Nucleocapsid pAb | ||||||||||||||||
|
||||||||||||||||||
Rabbit Anti-SARS-CoV-2 Nucleocapsid pAb | Anmelden | Rabbit Anti-SARS-CoV-2 Nucleocapsid pAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike S2 (Clone AbF712) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike S2 (Clone AbF712) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike S2 (Clone AbF712) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike S2 (Clone AbF712) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike S2 (Clone AbH722) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike S2 (Clone AbH722) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike S2 (Clone AbH722) mAb | Anmelden | Human Anti-SARS-CoV-2 Spike S2 (Clone AbH722) mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab(LY-CoV555) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab(LY-CoV555) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab(LY-CoV555) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Bamlanivimab(LY-CoV555) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Cilgavimab (AZD1061) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb | Anmelden | Human Anti-SARS-CoV-2 Spike-RBD Tixagevimab (AZD8895) Neutralizing mAb | ||||||||||||||||
|
||||||||||||||||||
Mouse Anti-Human Integrin alpha-V beta-3 (Clone BV3) mAb | Anmelden | Mouse Anti-Human Integrin alpha-V beta-3 (Clone BV3) mAb | ||||||||||||||||
|
||||||||||||||||||
Mouse Anti-Human Integrin alpha V/beta 3 (Clone BV4) mAb | Anmelden | Mouse Anti-Human Integrin alpha V/beta 3 (Clone BV4) mAb | ||||||||||||||||
|
||||||||||||||||||
Mouse Anti-Human Integrin alpha V / CD51 (Clone 23C6) mAb | Anmelden | Mouse Anti-Human Integrin alpha V / CD51 (Clone 23C6) mAb | ||||||||||||||||
|
||||||||||||||||||
Mouse Anti-Human Vitronectin/VTN Clone BV1 mAb | Anmelden | Mouse Anti-Human Vitronectin/VTN Clone BV1 mAb | ||||||||||||||||
|
||||||||||||||||||
Mouse Anti-Ribonucleoprotein particles mAb Clone 58-15 mAb | Anmelden | Mouse Anti-Ribonucleoprotein particles mAb Clone 58-15 mAb | ||||||||||||||||
|
||||||||||||||||||
D-Ribose(mixture of isomers) | Anmelden | D-Ribose(mixture of isomers) | ||||||||||||||||
|
||||||||||||||||||
PF00835231 | Anmelden | PF00835231 | ||||||||||||||||
|